Get the Stockscreener App
4.16
0.00%
0.00
After Hours:
4.18
0.02
+0.48%
Bluebird Bio Inc stock is traded at $4.16, with a volume of 47,856.
It is up +0.00% in the last 24 hours and up +8.05% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$4.16
Open:
$4.12
24h Volume:
47,856
Relative Volume:
0.12
Market Cap:
$38.18M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-5.6216
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
+0.48%
1M Performance:
+8.05%
6M Performance:
-56.68%
1Y Performance:
-77.21%
1-Day Range:
$4.0707
$4.20
1-Week Range:
$3.83
$4.565
52-Week Range:
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.16 | 38.18M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement | BLUE Stock News - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - marketscreener.com
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
Gene Therapy Market Insights 2025Trends, Growth Forecast & - openPR.com
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
Sickle Cell Disease Treatment Market to Hit $7.04 Billion By 2032 - openPR.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy - Docwire News
Companies team up to support sickle cell gene therapy Lyfgenia - Sickle Cell Disease News
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):